<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-132322" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Neuroretinitis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Rupa</given-names>
          </name>
          <aff>Manchester Royal Eye Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Bhupendra C.</given-names>
          </name>
          <aff>University of Utah</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chauhan</surname>
            <given-names>Shaylika</given-names>
          </name>
          <aff>Geisinger Health System</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rupa Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Bhupendra Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shaylika Chauhan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>19</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-132322.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Neuroretinitis is an uncommon type of optic disc swelling with characteristic retinal macular exudates and must be differentiated from other types of optic disc swelling. This activity reviews the presentation, etiologies, investigation, and treatment of neuroretinitis. This activity also highlights the role that the interprofessional team in managing neuroretinitis when associated with systemic disease.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the appearance of neuroretinitis.</p></list-item><list-item><p>Identify the 3 of the most common conditions associated with neuroretinitis.</p></list-item><list-item><p>Classify the types of neuroretinitis.</p></list-item><list-item><p>Outline the risk factors that should inform the line of questioning in taking histories from these patients for management by the interprofessional team.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=132322&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=132322">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-132322.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Neuroretinitis (NR) is defined as inflammation of the&#x000a0;anterior optic nerve and peripapillary retina.&#x000a0; It presents as&#x000a0;a triad of vision loss, optic disc swelling, and macular exudates in the formation of a star. It is a term given to the appearance but does not indicate a specific etiology.&#x000a0;</p>
        <p>Theodor Leber first described neuroretinitis in 1916,&#x000a0;and&#x000a0;the name&#x000a0;'stellate maculopathy' was coined.&#x000a0; As this term denotes, the original site of pathology was thought to be in the macula.&#x000a0; However, a subsequent study showed that the&#x000a0;fluid leakage at the optic disc&#x000a0;precedes the macular star, affecting the macula secondarily.<xref ref-type="bibr" rid="article-132322.r1">[1]</xref>&#x000a0;Thus, the term neuroretinitis was born.&#x000a0;</p>
        <p>The associated infectious and inflammatory etiologies now associated with neuroretinitis have been widely documented, and although the majority of cases self-resolve, it is important to understand where resolution may be minimal or where the disease may be recurrent and therefore require early treatment.&#x000a0;</p>
        <p>Neuroretinitis&#x000a0;is broadly categorized as idiopathic, idiopathic-recurrent, and cat scratch-disease neuroretinitis (CSD-NR).&#x000a0;Neuroretinitis may also be categorized based upon the etiology: infectious vs. non-infectious. Idiopathic and idiopathic-recurrent&#x000a0;neuroretinitis are&#x000a0;usually non-infectious.&#x000a0;It&#x000a0;is usually unilateral, but bilateral cases have been described, though they should lead the physician to consider other causes.</p>
      </sec>
      <sec id="article-132322.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Cat-scratch disease, caused by infection with the Bartonella henselae bacterium, has consistently been shown to be the most common cause of neuroretinitis and accounts for two-thirds of cases.<xref ref-type="bibr" rid="article-132322.r2">[2]</xref><xref ref-type="bibr" rid="article-132322.r3">[3]</xref>&#x000a0;Cat-scratch disease can also cause other ocular findings, including Parinaud oculoglandular syndrome, multifocal retinitis, uveitis, retinal vasculitis, and retinal detachment.<xref ref-type="bibr" rid="article-132322.r4">[4]</xref>&#x000a0;However, a large study of 107 eyes in 86 patients with confirmed cat-scratch disease found that neuroretinitis was the predominant manifestation in 88%.<xref ref-type="bibr" rid="article-132322.r5">[5]</xref>&#x000a0;&#x000a0;</p>
        <p>Other infectious causes include:<xref ref-type="bibr" rid="article-132322.r6">[6]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Lyme disease (Borrelia burgdorferi)</p>
          </list-item>
          <list-item>
            <p>Syphilis</p>
          </list-item>
          <list-item>
            <p>Tuberculosis</p>
          </list-item>
          <list-item>
            <p>Salmonella</p>
          </list-item>
          <list-item>
            <p>Varicella</p>
          </list-item>
          <list-item>
            <p>Herpes simplex and zoster</p>
          </list-item>
          <list-item>
            <p>Measles</p>
          </list-item>
          <list-item>
            <p>Mumps</p>
          </list-item>
          <list-item>
            <p>Rubella</p>
          </list-item>
          <list-item>
            <p>West Nile</p>
          </list-item>
          <list-item>
            <p>Zika</p>
          </list-item>
          <list-item>
            <p>Chikungunya</p>
          </list-item>
          <list-item>
            <p>Influenza</p>
          </list-item>
          <list-item>
            <p>Hepatitis</p>
          </list-item>
          <list-item>
            <p>Epstein-Barr virus</p>
          </list-item>
          <list-item>
            <p>Histoplasmosis</p>
          </list-item>
          <list-item>
            <p>Coccidioidomycosis</p>
          </list-item>
          <list-item>
            <p>Actinomycosis</p>
          </list-item>
          <list-item>
            <p>Toxoplasmosis</p>
          </list-item>
          <list-item>
            <p>Toxocariasis</p>
          </list-item>
          <list-item>
            <p>Diffuse unilateral subacute neuroretinitis</p>
          </list-item>
          <list-item>
            <p>Hepatitis B</p>
          </list-item>
          <list-item>
            <p>Leptospirosis</p>
          </list-item>
          <list-item>
            <p>Mumps</p>
          </list-item>
          <list-item>
            <p>Typhus</p>
          </list-item>
        </list>
        <p>Inflammatory causes include:<xref ref-type="bibr" rid="article-132322.r6">[6]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Sarcoidosis</p>
          </list-item>
          <list-item>
            <p>Systemic lupus erythematosus</p>
          </list-item>
          <list-item>
            <p>Behcet disease</p>
          </list-item>
          <list-item>
            <p>Polyarteritis nodosa</p>
          </list-item>
          <list-item>
            <p>Takasayu's arteritis</p>
          </list-item>
          <list-item>
            <p>Vogt-Koyanagi-Harada</p>
          </list-item>
          <list-item>
            <p>Inflammatory bowel disease has also rarely been associated with NR.</p>
          </list-item>
        </list>
        <p>Fifty percent of cases have no identifiable cause and are labeled idiopathic neuroretinitis.<xref ref-type="bibr" rid="article-132322.r7">[7]</xref></p>
      </sec>
      <sec id="article-132322.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The incidence and prevalence of NR have not been determined. Still, it is thought to be underdiagnosed due to the temporal dissociation of disc edema and macular star formation, which follows after&#x000a0;1&#x000a0;to 2 weeks.&#x000a0;</p>
        <p>Neuroretinitis of all types usually affects young adults between 8 and 40 years with a median of 24 years. CSD-NR affects females more than males with a ratio of 1.8&#x000a0;to 1, and idiopathic and idiopathic-recurrent does not appear to have a sex predilection.&#x000a0;There is some&#x000a0;suggestion&#x000a0;that geographically,&#x000a0;neuroretinitis&#x000a0;may be more common in the Mid-Western United States, but this is unconfirmed.<xref ref-type="bibr" rid="article-132322.r8">[8]</xref></p>
      </sec>
      <sec id="article-132322.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The use of fluorescein angiography by Gass in 1977 was the first to show&#x000a0;that edema in neuroretinitis emanates from the optic disc rather than from within the macula.<xref ref-type="bibr" rid="article-132322.r1">[1]</xref>&#x000a0;A study of disease progression in one patient with neuroretinitis used fluorescein angiography and optical coherence tomography to demonstrate the development of fluid spaces within the outer plexiform layer of the retina in the peripapillary region.<xref ref-type="bibr" rid="article-132322.r9">[9]</xref>&#x000a0;The aqueous phase of the fluid then passes through the external limiting membrane to collect in the subretinal space.&#x000a0;The edema gradually resolves to leave lipid-rich exudates within the outer plexiform layer, which appear in a stellate formation due to the radial arrangement of fibers within this layer.&#x000a0;&#x000a0;</p>
        <p>The mechanism of inflammation and vasculitis is unknown, but&#x000a0;it is generally thought it may&#x000a0;be due to either direct infection or an autoimmune process.<xref ref-type="bibr" rid="article-132322.r10">[10]</xref>&#x000a0;In cat-scratch disease, in particular, a direct vascular invasion method is thought to predominate. This has been suggested due to the evidence of vasculitic leakage in the other posterior segment ocular manifestations of cat-scratch disease, including multifocal chorioretinitis and segmental disc swelling consistent with&#x000a0;the perfusion patterns of the ciliary and central arteriolar vessels.<xref ref-type="bibr" rid="article-132322.r8">[8]</xref></p>
      </sec>
      <sec id="article-132322.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Vision loss in&#x000a0;neuroretinitis&#x000a0;is usually unilateral but can be bilateral. The first presentation is with disc swelling of any degree. This may or may not be associated with flame hemorrhages at the disc. Other features such as very severe swelling or retinal vascular occlusion should prompt the physician to consider other disease processes.&#x000a0; Subretinal and intraretinal fluid may be noted in the peripapillary region, which can be missed but seen on optical coherence tomography (OCT).&#x000a0; Fluid from the optic disc&#x000a0;tracks directly into the outer nuclear-plexiform layers of the retina and accumulates in the subretinal space giving rise in some cases to a focal macular detachment of the neurosensory retina.<xref ref-type="bibr" rid="article-132322.r9">[9]</xref> With the resolution of the disc edema and retinal/subretinal fluid, lipid-rich exudates are left behind in a stellate formation. This is seen after around 3 weeks. It is thought that the longer the subretinal fluid persists, the more damage may occur to the photoreceptors and thus may be an indicator for treatment initiation.&#x000a0;</p>
        <p>Vision is often reduced and can range between 20/20 to light perception and can tend&#x000a0;to be worse in CSD-NR and recurrent-idiopathic neuroretinitis.<xref ref-type="bibr" rid="article-132322.r8">[8]</xref>&#x000a0;The pattern of visual field loss varies greatly but is generally central or ceco-central in the majority of cases. Idiopathic-recurrent neuroretinitis&#x000a0;may&#x000a0;also involve a nerve fiber bundle&#x000a0;giving&#x000a0;rise to a central scotoma&#x000a0;with an arcuate defect. Pain within the eye or retro-orbital area is uncommonly noted.&#x000a0; If severe pain is noted, an alternative diagnosis&#x000a0;should be ruled out.&#x000a0;</p>
        <p>A mild to moderate relative afferent pupillary defect (RAPD)&#x000a0;is seen in many cases, and in particular, around two-thirds of CSD-NR.&#x000a0;However, the absence or presence of an RAPD does not include or rule out neuroretinitis.&#x000a0;Posterior vitreous cells can also be seen,&#x000a0;alluding to&#x000a0;the inflammatory nature of the disease.</p>
        <p>Careful history-taking is essential, and one must inquire about any preceding flu-like prodrome, but also around the risk factors for Lyme disease (tick bite and erythema migrans), sexually transmitted infections, as well as risk factors for tuberculosis.&#x000a0; As with every neuro-ophthalmic case, a detailed systemic review and travel history must also be carried out.</p>
      </sec>
      <sec id="article-132322.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Where&#x000a0;available, useful laboratory tests&#x000a0;include syphilis and tuberculosis testing, along with Bartonella and Borrelia serology.&#x000a0;&#x000a0;</p>
        <p>Optical coherence tomography (OCT) is an exceptionally useful tool to image the optic disc and macula to identify subretinal fluid and intra-retinal edema that may otherwise be missed on clinical examination in the early phases of the process.&#x000a0; Findings of flattening of the foveal contour, fluid within the outer plexiform layer, and/or subretinal fluid along with early intraretinal exudates can suggest the diagnosis of neuroretinitis before the appearance of a macular star.<xref ref-type="bibr" rid="article-132322.r7">[7]</xref> Very early on, collections of cells in the vitreous&#x000a0;anterior to the optic disc may be seen on OCT before they are visible in the anterior vitreous on slit-lamp biomicroscopy.<xref ref-type="bibr" rid="article-132322.r11">[11]</xref>&#x000a0;</p>
        <p>This finding is crucial to note in equivocal cases as it will&#x000a0;differentiate inflammatory/infective etiologies of disc swelling from non-inflammatory ones such as papilledema and ischemic optic neuropathy. Furthermore, the degree of subretinal and intraretinal fluid, along with the degree of optic disc swelling, can be quantified and monitored with serial OCTs. This can enable the physician to identify the likelihood or not of&#x000a0;visual recovery within the first few weeks. Again, it is important to note when subretinal fluid is extensive or persistent as this may indicate a lower likelihood of visual recovery.&#x000a0;</p>
        <p>Fundus fluorescein angiography is a safe and useful tool to determine the site of leakage, identify other less visible retinal and retinal vascular pathologies such as vasculitis, occlusion, and document diabetic or hypertensive retinopathy. With neuroretinitis, leakage should begin in the optic disc and maybe segmental. It may also identify a single anterior optic disc vessel source.&#x000a0; It will also highlight subtle edema within the contralateral optic disc where bilateral pathology may otherwise be overlooked.</p>
        <p>MRI is&#x000a0;often normal but may show enhancement of the optic disc and may extend a few millimeters posteriorly within the intraorbital portion of the optic nerve.<xref ref-type="bibr" rid="article-132322.r8">[8]</xref>&#x000a0; The optic nerve sheath may enhance in rarer cases.<xref ref-type="bibr" rid="article-132322.r12">[12]</xref>&#x000a0;This form of imaging should be completed in any case where the diagnosis is not certain and is essential to rule out other optic nerve inflammatory or compressive conditions that may be treatable.</p>
      </sec>
      <sec id="article-132322.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>There is no consensus regarding optimal treatment, owing to the wide variability in etiologies, relatively uncommon prevalence, and the majority of cases being self-limiting. If a causative organism or disease has been identified, then that&#x000a0;requires treatment.&#x000a0;It is agreed that most idiopathic cases and&#x000a0;most&#x000a0;CSD-NR will spontaneously resolve. However, there are no randomized clinical trials to determine the best course of action in these or other cases, and current literature is still in debate.&#x000a0;</p>
        <p>To treat systemic cat-scratch disease, presenting with fever and lymphadenopathy, a prospective randomized clinical trial showed that a course of azithromycin more rapidly reduces lymph node volume than without treatment.<xref ref-type="bibr" rid="article-132322.r13">[13]</xref>&#x000a0;</p>
        <p>Treatment regimens analyzed in retrospective series of CSD-NR include antibiotics, steroids, and antibiotics with steroids. Antibiotics commonly used include azithromycin, ciprofloxacin,&#x000a0;or doxycycline in combination with rifampin.&#x000a0; These have been purported to hasten recovery, but statistical conclusions cannot be drawn due to the vast majority being self-limiting, particularly in immunocompetent patients.</p>
        <p>A more recent review of evidence and expert opinion concluded that for patients with severe vision loss and/or moderate to severe systemic, systemic symptoms, treatment with doxycycline or azithromycin with rifampin for a duration of 4-6 weeks may provide benefit, and that routine use of steroids is not recommended.<xref ref-type="bibr" rid="article-132322.r7">[7]</xref>&#x000a0;</p>
        <p>For recurrent cases of neuroretinitis, long-term immunosuppression with azithromycin may be necessary.</p>
      </sec>
      <sec id="article-132322.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Other conditions that may cause disc swelling with subretinal fluid or macular star include hypertensive retinopathy (which is usually bilateral), papilledema (usually bilateral or asymmetric), anterior ischemic optic neuropathy, vasculitis, and diabetic papillopathy. Hence, it is essential to check each patient's blood pressure and heart rate, enquire about&#x000a0;symptoms of raised intracranial pressure&#x000a0;and systemic conditions.</p>
      </sec>
      <sec id="article-132322.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>In idiopathic NR and CSD-NR cases, 97%&#x000a0;have a final visual acuity of 20/40 or better. However, in idiopathic-recurrent NR, cumulative damage results in a final vision of &#x0003e;20/40 in only 36%.<xref ref-type="bibr" rid="article-132322.r8">[8]</xref><xref ref-type="bibr" rid="article-132322.r14">[14]</xref>&#x000a0;Depending upon the severity of the attack, sectoral or diffuse optic disk pallor may ensue, indicating that permanent neuronal loss has occurred.</p>
      </sec>
      <sec id="article-132322.s11" sec-type="Complications">
        <title>Complications</title>
        <p>In cases of recurrent or severe infectious neuroretinitis, vision may be permanently affected with a reduction in acuity or defect in the visual field.&#x000a0; Hence, those with severe vision loss, field defects, or immune compromise are best treated.&#x000a0; Other systemic complications depend upon the underlying condition.</p>
      </sec>
      <sec id="article-132322.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>There are no proven deterrent advisories for this condition. However, where there is significant vision loss affecting daily life activities, further help can be sought, where available, to provide practical low-visual aids such as magnifiers and lighting equipment to enhance visual function.</p>
      </sec>
      <sec id="article-132322.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The clinical diagnosis of neuroretinitis may be an easy one. However, its management can be complicated. Where an underlying condition is identified, this must be managed by the relevant subspecialty physician, and monitoring of the disease should be carried out to ensure resolution of the ophthalmic presentation follows.</p>
        <p>Further advice and input should be sought from internal medicine physicians or infectious diseases specialists where relevant.&#x000a0;</p>
        <p>In cases of severe vision loss, referral to a low vision clinic to provide holistic support and practical aids&#x000a0;for daily living will enable the patient to continue to be as independent as possible.</p>
        <p>Management of&#x000a0;neuroretinitis requires the efforts of an interprofessional healthcare team, including clinicians, specialists, mid-level practitioners, nurses, and pharmacists, all working and communicating collaboratively to achieve optimal patient outcomes. [Level 5]</p>
      </sec>
      <sec id="article-132322.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=132322&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=132322">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/eye-health/neuroretinitis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=132322">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/132322/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=132322">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-132322.s15">
        <fig id="article-132322.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Neuroretinitis in an 18-year-old female who presented with vision loss in the right eye, headaches and severe photophobia
A: Multispectral image shows right optic nerve edema at presentation
B: Shows resolution of the edema
C: Fundus autofluorescence of the right eye on presentation shows hypoautofluorescence surrounding the optic nerve
D: Improvement of the hyposutofluorescence with resolution of the condition Contributed by https://morancore.utah.edu/section-09-intraocular-inflammation-and-uveitis/neuroretinitis-the-great-masquerader/</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="27019_Modersitzki_Neuroretinitis_Figure_1-e1568655121212" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-132322.s16">
        <title>References</title>
        <ref id="article-132322.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gass</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Diseases of the optic nerve that may simulate macular disease.</article-title>
            <source>Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol</source>
            <year>1977</year>
            <season>Sep-Oct</season>
            <volume>83</volume>
            <issue>5</issue>
            <fpage>763</fpage>
            <page-range>763-70</page-range>
            <pub-id pub-id-type="pmid">73251</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132322.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suhler</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Lauer</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Rosenbaum</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of serologic evidence of cat scratch disease in patients with neuroretinitis.</article-title>
            <source>Ophthalmology</source>
            <year>2000</year>
            <month>May</month>
            <volume>107</volume>
            <issue>5</issue>
            <fpage>871</fpage>
            <page-range>871-6</page-range>
            <pub-id pub-id-type="pmid">10811077</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132322.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kahloun</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Khairallah-Ksiaa</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Abroug</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mahmoud</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ben Yahia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zaouali</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jelliti</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Khairallah</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Final Diagnosis in Patients Referred with a Diagnosis of Neuroretinitis.</article-title>
            <source>Neuroophthalmology</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>39</volume>
            <issue>6</issue>
            <fpage>266</fpage>
            <page-range>266-270</page-range>
            <pub-id pub-id-type="pmid">27928367</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132322.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cunningham</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Koehler</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Ocular bartonellosis.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2000</year>
            <month>Sep</month>
            <volume>130</volume>
            <issue>3</issue>
            <fpage>340</fpage>
            <page-range>340-9</page-range>
            <pub-id pub-id-type="pmid">11020414</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132322.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Habot-Wilner</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Trivizki</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kesler</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shulman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Horowitz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Amer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>David</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ben-Arie-Weintrob</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Bakshi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Almog</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sartani</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vishnevskia-Dai</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kramer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kehat</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ephros</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Giladi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cat-scratch disease: ocular manifestations and treatment outcome.</article-title>
            <source>Acta Ophthalmol</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>96</volume>
            <issue>4</issue>
            <fpage>e524</fpage>
            <page-range>e524-e532</page-range>
            <pub-id pub-id-type="pmid">29504674</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132322.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abdelhakim</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rasool</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Neuroretinitis: a review.</article-title>
            <source>Curr Opin Ophthalmol</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>29</volume>
            <issue>6</issue>
            <fpage>514</fpage>
            <page-range>514-519</page-range>
            <pub-id pub-id-type="pmid">30148725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132322.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fairbanks</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Starr</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Bhatti</surname>
                <given-names>MT</given-names>
              </name>
            </person-group>
            <article-title>Treatment Strategies for Neuroretinitis: Current Options and Emerging Therapies.</article-title>
            <source>Curr Treat Options Neurol</source>
            <year>2019</year>
            <month>Jul</month>
            <day>05</day>
            <volume>21</volume>
            <issue>8</issue>
            <fpage>36</fpage>
            <pub-id pub-id-type="pmid">31278547</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132322.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Purvin</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sundaram</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kawasaki</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Neuroretinitis: review of the literature and new observations.</article-title>
            <source>J Neuroophthalmol</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>31</volume>
            <issue>1</issue>
            <fpage>58</fpage>
            <page-range>58-68</page-range>
            <pub-id pub-id-type="pmid">21317731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132322.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kitamei</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Katsuta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yokoi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kase</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Retinal angiography and optical coherence tomography disclose focal optic disc vascular leakage and lipid-rich fluid accumulation within the retina in a patient with leber idiopathic stellate neuroretinitis.</article-title>
            <source>J Neuroophthalmol</source>
            <year>2009</year>
            <month>Sep</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>203</fpage>
            <page-range>203-7</page-range>
            <pub-id pub-id-type="pmid">19726942</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132322.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maitland</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>NR</given-names>
              </name>
            </person-group>
            <article-title>Neuroretinitis.</article-title>
            <source>Arch Ophthalmol</source>
            <year>1984</year>
            <month>Aug</month>
            <volume>102</volume>
            <issue>8</issue>
            <fpage>1146</fpage>
            <page-range>1146-50</page-range>
            <pub-id pub-id-type="pmid">6466175</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132322.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zatreanu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sibony</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Kupersmith</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Optical Coherence Tomography in Neuroretinitis: Epipapillary Infiltrates and Retinal Folds.</article-title>
            <source>J Neuroophthalmol</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>37</volume>
            <issue>2</issue>
            <fpage>176</fpage>
            <page-range>176-178</page-range>
            <pub-id pub-id-type="pmid">28418948</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132322.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wals</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Ansari</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kiss</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Langton</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Silver</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Odel</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Simultaneous occurrence of neuroretinitis and optic perineuritis in a single eye.</article-title>
            <source>J Neuroophthalmol</source>
            <year>2003</year>
            <month>Mar</month>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>24</fpage>
            <page-range>24-7</page-range>
            <pub-id pub-id-type="pmid">12616085</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132322.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bass</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Freitas</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Freitas</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Sisler</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Person</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Claybaugh</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Wittler</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Weisse</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Regnery</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Slater</surname>
                <given-names>LN</given-names>
              </name>
            </person-group>
            <article-title>Prospective randomized double blind placebo-controlled evaluation of azithromycin for treatment of cat-scratch disease.</article-title>
            <source>Pediatr Infect Dis J</source>
            <year>1998</year>
            <month>Jun</month>
            <volume>17</volume>
            <issue>6</issue>
            <fpage>447</fpage>
            <page-range>447-52</page-range>
            <pub-id pub-id-type="pmid">9655532</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132322.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dreyer</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Hopen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gass</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Leber's idiopathic stellate neuroretinitis.</article-title>
            <source>Arch Ophthalmol</source>
            <year>1984</year>
            <month>Aug</month>
            <volume>102</volume>
            <issue>8</issue>
            <fpage>1140</fpage>
            <page-range>1140-5</page-range>
            <pub-id pub-id-type="pmid">6466174</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
